MX2021005293A - Conjugados de interleuquina 10 y usos de los mismos. - Google Patents

Conjugados de interleuquina 10 y usos de los mismos.

Info

Publication number
MX2021005293A
MX2021005293A MX2021005293A MX2021005293A MX2021005293A MX 2021005293 A MX2021005293 A MX 2021005293A MX 2021005293 A MX2021005293 A MX 2021005293A MX 2021005293 A MX2021005293 A MX 2021005293A MX 2021005293 A MX2021005293 A MX 2021005293A
Authority
MX
Mexico
Prior art keywords
conjugates
interleukin
kits
indications
treatment
Prior art date
Application number
MX2021005293A
Other languages
English (en)
Inventor
Jerod Ptacin
Carolina E Caffaro
Marcos Milla
Original Assignee
Synthorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthorx Inc filed Critical Synthorx Inc
Publication of MX2021005293A publication Critical patent/MX2021005293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugados de interleuquina 10 y sus usos en el tratamiento de una o más indicaciones. Composiciones farmacéuticas y kits que comprenden uno o más de los conjugados de IL-10.
MX2021005293A 2018-11-08 2019-11-07 Conjugados de interleuquina 10 y usos de los mismos. MX2021005293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862757690P 2018-11-08 2018-11-08
US201962911036P 2019-10-04 2019-10-04
PCT/US2019/060261 WO2020097325A1 (en) 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2021005293A true MX2021005293A (es) 2021-06-23

Family

ID=70612119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005293A MX2021005293A (es) 2018-11-08 2019-11-07 Conjugados de interleuquina 10 y usos de los mismos.

Country Status (16)

Country Link
US (1) US20210338829A1 (es)
EP (1) EP3876973A4 (es)
JP (1) JP2022506531A (es)
KR (1) KR20210091170A (es)
CN (1) CN113260374A (es)
AU (1) AU2019376076A1 (es)
BR (1) BR112021005401A2 (es)
CA (1) CA3117572A1 (es)
CO (1) CO2021003530A2 (es)
IL (1) IL282736A (es)
MA (1) MA54195A (es)
MX (1) MX2021005293A (es)
PH (1) PH12021550611A1 (es)
SG (1) SG11202102930YA (es)
TW (1) TW202031284A (es)
WO (1) WO2020097325A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018309166B2 (en) 2017-08-03 2022-12-08 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019165453A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
SG11202107354WA (en) 2019-02-06 2021-08-30 Synthorx Inc Il-2 conjugates and methods of use thereof
CH716227B1 (it) * 2020-04-16 2020-11-30 Contrad Swiss Sa Composizione in gel per applicazione topica per la riduzione dell'infiammazione locale.
JP2023548045A (ja) 2020-10-23 2023-11-15 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
AU2021396247A1 (en) * 2020-12-09 2023-07-06 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
CN112618699A (zh) * 2020-12-31 2021-04-09 深圳先进技术研究院 一种能够提供治疗有效量的白介素10的试剂及其抗肿瘤应用
KR20240024235A (ko) * 2021-07-29 2024-02-23 노보코덱스 바이오파마슈티컬즈 컴퍼니 리미티드 비천연 아미노산, 및 이의 용도, 이를 함유하는 재조합 단백질, 및 재조합 단백질 컨주게이트

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
EP1610825A2 (en) * 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
WO2013130913A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
ES2688206T3 (es) * 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
EP3341012A4 (en) * 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CN113366015A (zh) * 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途

Also Published As

Publication number Publication date
EP3876973A1 (en) 2021-09-15
KR20210091170A (ko) 2021-07-21
US20210338829A1 (en) 2021-11-04
IL282736A (en) 2021-06-30
PH12021550611A1 (en) 2021-10-04
MA54195A (fr) 2022-02-16
SG11202102930YA (en) 2021-04-29
EP3876973A4 (en) 2022-08-03
TW202031284A (zh) 2020-09-01
CA3117572A1 (en) 2020-05-14
AU2019376076A1 (en) 2021-04-15
WO2020097325A1 (en) 2020-05-14
JP2022506531A (ja) 2022-01-17
CO2021003530A2 (es) 2021-04-19
CN113260374A (zh) 2021-08-13
BR112021005401A2 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
PH12020551261A1 (en) Il-15 conjugates and uses thereof
PH12021550611A1 (en) Interleukin 10 Conjugates and Uses Thereof
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
WO2018229236A3 (en) COMPOSITIONS COMPRISING BACTERIAL STRAINS
MX2021002415A (es) Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
EP4310500A3 (en) Methods and compositons for the activation of gamma-delta t-cells
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2020009733A (es) Composiciones.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2021004517A (es) Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
MX2021000719A (es) Composicion de microbiota fecal, para su uso en la reduccion de la inflamacion inducida por tratamiento.
MX2022005251A (es) Conjugados de interleuquina 10 y sus usos.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2022000712A (es) Moduladores de nlrp3.
WO2021004958A3 (en) Compositions comprising bacterial strains
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.